Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGFβR-KO CAR-EGFR T Cells in Advanced EGFR-positive Solid Tumors
NCT04976218Phase 1Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TGFβR-KO CAR-EGFR T Cells in solid tumor, sponsored by Chinese PLA General Hospital. Primary endpoint: Number of subjects occuring treatment related adverse events up to 24 weeks. Status: unknown.
02
Drugs
TGFβR-KO CAR-EGFR T Cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04976218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976218.